Omeros Corporation Company Profile (NASDAQ:OMER)

About Omeros Corporation

Omeros Corporation logoOmeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: OMER
  • CUSIP: 68214310
Key Metrics:
  • Previous Close: $10.74
  • 50 Day Moving Average: $11.59
  • 200 Day Moving Average: $12.24
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.65
  • P/E Growth: -0.09
  • Market Cap: $422.01M
  • Outstanding Shares: 39,293,000
  • Beta: 2.16
Additional Links:
Companies Related to Omeros Corporation:

Analyst Ratings

Consensus Ratings for Omeros Corporation (NASDAQ:OMER) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $39.50 (267.78% upside)

Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016WedbushReiterated RatingOutperform$62.00 -> $56.00View Rating Details
8/10/2016Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details
8/10/2016Maxim GroupLower Price TargetBuy$30.00 -> $19.00View Rating Details
6/29/2016FBR & CoReiterated RatingOutperform$38.00View Rating Details
6/14/2016WBB SecuritiesReiterated RatingBuy$75.00View Rating Details
3/2/2016Needham & Company LLCLower Price TargetBuy$30.00 -> $28.00View Rating Details
8/19/2015Roth CapitalReiterated RatingBuy$38.00View Rating Details
8/18/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$38.00View Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Omeros Corporation (NASDAQ:OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
Current Year EPS Consensus Estimate: $-1.51 EPS
Next Year EPS Consensus Estimate: $-0.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.52)($0.42)($0.47)
Q2 20163($0.52)($0.31)($0.43)
Q3 20163($0.31)($0.22)($0.27)
Q4 20163($0.33)($0.12)($0.22)
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.02)($0.02)($0.02)
Q3 20171$0.11$0.11$0.11
Q4 20171$0.19$0.19$0.19
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Omeros Corporation (NASDAQ:OMER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Omeros Corporation (NASDAQ:OMER)
DateHeadline
seekingalpha.com logoReassessing My Thesis On Omeros - Seeking Alpha (NASDAQ:OMER)
seekingalpha.com - August 23 at 11:04 AM
live-pr.com logo"Omeros Corporation (OMER) - Financial and Strategic SWOT Analysis Review" Published (NASDAQ:OMER)
www.live-pr.com - August 19 at 6:33 PM
News IconOmeros Corporation (NASDAQ:OMER) To Give A Presentation At The Wedbush PacGrow Conference - Journal Transcript (NASDAQ:OMER)
www.journaltranscript.com - August 18 at 6:48 PM
finance.yahoo.com logoOMEROS CORP Financials (NASDAQ:OMER)
finance.yahoo.com - August 18 at 6:48 PM
capitalcube.com logoOmeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : August 17, 2016 (NASDAQ:OMER)
www.capitalcube.com - August 17 at 9:43 AM
News IconTrader's Watch List: Omeros Corporation (NASDAQ:OMER), Rennova Health Inc (NASDAQ:RNVA) - NYSE Journal (press release) (NASDAQ:OMER)
stockznews.com - August 16 at 9:53 AM
4-traders.com logoOMEROS CORP : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:OMER)
www.4-traders.com - August 15 at 6:56 PM
capitalcube.com logoETF’s with exposure to Omeros Corp. : August 15, 2016 (NASDAQ:OMER)
www.capitalcube.com - August 15 at 6:56 PM
biz.yahoo.com logoOMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex (NASDAQ:OMER)
biz.yahoo.com - August 15 at 6:56 PM
seekingalpha.com logoOmeros Corp.'s Path Ahead (NASDAQ:OMER)
seekingalpha.com - August 13 at 9:32 AM
seekingalpha.com logoOmeros Corp.'s Path Ahead - Seeking Alpha (NASDAQ:OMER)
seekingalpha.com - August 12 at 6:45 PM
capitalcube.com logoOmeros Corp. :OMER-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:OMER)
www.capitalcube.com - August 12 at 6:45 PM
News IconTrading the Biotech News: Incyte Corporation (NASDAQ:INCY), Omeros Corporation (NASDAQ:OMER) - The Voice Registrar (NASDAQ:OMER)
voiceregistrar.com - August 12 at 9:49 AM
fool.com logoWhy Omeros Corporation's Stock Dropped Today - Motley Fool (NASDAQ:OMER)
www.fool.com - August 12 at 9:49 AM
finance.yahoo.com logoOmeros to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:OMER)
finance.yahoo.com - August 12 at 9:49 AM
News IconBiopharm Company Raising $40 Million in IPO (NASDAQ:OMER)
sciencebusiness.technewslit.com - August 11 at 7:05 PM
bizjournals.com logoOmeros selling $40M in shares (NASDAQ:OMER)
www.bizjournals.com - August 11 at 7:05 PM
publicnow.com logoOmeros Announces Pricing of Public Offering of Common Stock (NASDAQ:OMER)
www.publicnow.com - August 11 at 7:05 PM
fool.com logoWhy Omeros Corporation's Stock Dropped Today (NASDAQ:OMER)
www.fool.com - August 11 at 7:05 PM
smarteranalyst.com logoCompany Update (NASDAQ:OMER): Omeros Corporation's Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in ... - Smarter Analyst (NASDAQ:OMER)
www.smarteranalyst.com - August 10 at 7:03 PM
publicnow.com logoOmeros Announces Public Offering of Common Stock (NASDAQ:OMER)
www.publicnow.com - August 10 at 7:03 PM
seekingalpha.com logoOmeros readies $40M equity offering; shares down 7% after hours (NASDAQ:OMER)
seekingalpha.com - August 10 at 5:43 PM
twst.com logoOmeros Corporation: Omeros Corporation Reports Second Quarter 2016 Financial Results (NASDAQ:OMER)
www.twst.com - August 10 at 9:44 AM
News IconOmeros Corporation Reports Second Quarter 2016 Financial Results (NASDAQ:OMER)
ih.advfn.com - August 10 at 9:44 AM
finance.yahoo.com logo7:03 am Omeros announces results from its OMS906 complement program; significantly improved the survival of red blood cells when compared to control-treated animals and to animals treated with a C5 inhibitor (NASDAQ:OMER)
finance.yahoo.com - August 10 at 9:44 AM
publicnow.com logoOmeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model (NASDAQ:OMER)
www.publicnow.com - August 10 at 9:44 AM
nasdaq.com logoEarnings Reaction History: Omeros Corporation, 57.1% Follow-Through Indicator, 7.6% Sensitive - Nasdaq (NASDAQ:OMER)
www.nasdaq.com - August 9 at 6:54 PM
businesswire.com logoOmeros Corporation Reports Second Quarter 2016 Financial Results - Business Wire (press release) (NASDAQ:OMER)
www.businesswire.com - August 9 at 6:54 PM
sg.finance.yahoo.com logoOmeros reports 2Q loss (NASDAQ:OMER)
sg.finance.yahoo.com - August 9 at 6:53 PM
biz.yahoo.com logoOmeros Corp Earnings Call (Q2 2016) (NASDAQ:OMER)
biz.yahoo.com - August 9 at 9:50 AM
biz.yahoo.com logoQ2 2016 Omeros Corp Earnings Release - After Market Close (NASDAQ:OMER)
biz.yahoo.com - August 9 at 9:50 AM
finance.yahoo.com logoMedical Product Stocks' Earnings on Aug 9: PEN, STE & More (NASDAQ:OMER)
finance.yahoo.com - August 8 at 11:19 AM
streetinsider.com logoOmeros (OMER) Announces Results from OMS906 Complement Program (NASDAQ:OMER)
www.streetinsider.com - August 5 at 6:52 PM
equities.com logoOmeros Corporation (OMER) Jumps 5.13% on August 03 - Equities.com (NASDAQ:OMER)
www.equities.com - August 5 at 9:43 AM
businesswire.com logoOmeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016 - Business Wire (press release) (NASDAQ:OMER)
www.businesswire.com - August 4 at 7:05 PM
News IconOmeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System (NASDAQ:OMER)
www.enhancedonlinenews.com - August 4 at 9:48 AM
publicnow.com logoOmeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016 (NASDAQ:OMER)
www.publicnow.com - August 4 at 9:48 AM
seekingalpha.com logoOmeros Q2 Preview: All Eyes On Omidria - Seeking Alpha (NASDAQ:OMER)
seekingalpha.com - August 3 at 7:00 PM
ftsenews.co.uk logoBrokers Issue Average Price Target Of 42.86 On Omeros Corporation (OMER) - FTSE News (NASDAQ:OMER)
www.ftsenews.co.uk - August 3 at 9:53 AM
marketexclusive.com logoA Look At Omeros Corporation (NASDAQ:OMER)’s Lead Rare Disease Focus (NASDAQ:OMER)
marketexclusive.com - July 29 at 6:45 PM
ftsenews.co.uk logoNew Broker Ratings For Omeros Corporation (OMER) - FTSE News (NASDAQ:OMER)
www.ftsenews.co.uk - July 28 at 9:49 AM
prnewswire.com logoOmeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency - PR Newswire (press release) (NASDAQ:OMER)
www.prnewswire.com - July 28 at 9:49 AM
publicnow.com logoOmeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency (NASDAQ:OMER)
www.publicnow.com - July 28 at 9:38 AM
News IconShares Stumbling of Late: Omeros Corporation (NASDAQ:OMER) - TGP (NASDAQ:OMER)
telanaganapress.com - July 23 at 10:33 AM
News IconStock Displaying Signs of a Downtrend: Omeros Corporation (NASDAQ:OMER) - Press Telegraph (NASDAQ:OMER)
presstelegraph.com - July 23 at 10:33 AM
News IconOmeros Corporation (NASDAQ:OMER): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:OMER)
www.engelwooddaily.com - July 21 at 6:57 PM
News IconEquity Roundup: Stock Performance Focus on Omeros Corporation (NASDAQ:OMER) - Press Telegraph (NASDAQ:OMER)
presstelegraph.com - July 20 at 7:23 PM
equities.com logoOmeros Corporation (OMER) Drops 6.96% on July 19 - Equities.com (NASDAQ:OMER)
www.equities.com - July 20 at 7:23 PM
capitalcube.com logoOmeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : July 20, 2016 (NASDAQ:OMER)
www.capitalcube.com - July 20 at 8:18 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Omeros Corporation (NASDAQ:OMER) - TGP (NASDAQ:OMER)
telanaganapress.com - July 19 at 8:00 AM

Social

Omeros Corporation (NASDAQ:OMER) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff